Hørsholm, Denmark, March 26th, 2020 – Oncology Venture A/S (”Oncology Venture”) today announced that members of its senior management team are scheduled to make a number of investor presentations during the second quarter of 2020. As some events may be changed to online events or cancelled in order to contain the spread of the COVID-19 virus, investors are encouraged to confirm the details of the events organized by third parties on the same day as they are scheduled to occur. Please, refer to the relevant URLs below for more details.
Investor meetings
| Date and time (CET) | Organizer | Place | About |
| March 31th 17.00 – 17.30
|
Oncology Venture
|
Online
|
Presentation and Q&A with the Executive Management team following the publication of the Annual Report 2019 Please register here to attend: http://bit.ly/2Wlhrjg |
| April 22th 15.00-16.00 |
Oncology Venture | Pharmakon Konferencecenter, Milnersvej 42, Hillerød, Denmark |
Annual General Meeting Please, refer to the notice to convene the annual general meeting (to be published) |
| May 4th 11.00 – 11.30
|
Aktiespararna
|
Operaterrassen, Karl XII:s torg 1, Stockholm, Sweden
|
Investor Presentation For attendance information: https://www.aktiespararna.se/aktiviteter/evenemang |
| May 11th 13.00 – 13.30 |
Sedermera Fondkommission | Clarion Malmö Live Dag Hammarskjölds Torg 2, Malmö, Sweden |
Investor Presentation Please register here to attend: https://sedermera.se/da/evenemang/2020-05-11/sedermeradagen-malmo-2020 |
For further information, please contact:
| For investor inquiries Henrik Moltke, CFO E-mail: [email protected] Telephone +45 21 70 10 49 |
About Oncology Venture A/S
Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics (cDx) generated by its proprietary drug response predictor technology, DRP®. The Company has three high-priority programs: 2X-121 – a PARP inhibitor in Phase 2 trials for treatment of ovarian cancer; IXEMPRA® (Ixabepilone) – an approved and marketed (U.S.) microtubule inhibitor being advanced for Phase 2 clinical development (in EU) for treatment of breast cancer; and Dovitinib – a pan-tyrosine kinase inhibitor (pan-TKI) that is post Phase 3 trials, being prepared for a U.S. new drug approval (NDA) filing in renal cell carcinoma (RCC).
About the Drug Response Predictor – DRP® Companion Diagnostic
Oncology Venture uses its drug-specific DRP® cDx to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and prior clinical trial outcomes. The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs in the U.S.
Follow us on social media:
Facebook: https://www.facebook.com/oncologyventure/
LinkedIn: https://www.linkedin.com/company/oncology-venture/
Twitter: https://twitter.com/OncologyVenture
Learn more at oncologyventure.com.
DRP® is a registered trademark of Oncology Venture A/S.
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OV’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OV’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OV undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Certified Adviser:
Svensk Kapitalmarknadsgranskning AB, Email: [email protected]. Tel: +46 11 32 30 732
Attachment
